MFG
ITCI

Mendota Financial Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Mendota Financial Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20
Closed -$1.22K – 391
2023
Q1 		$1.22K Buy
+20
New +$967 ﹤0.01% 284

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mendota Financial Group's ITCI Position: Q2 2023 in Review

Mendota Financial Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 20 shares — an estimated $1.22K sold.

Mendota Financial Group first reported a position in ITCI in Q1 2023 and held it in 1 quarter. The position peaked at $1.22K in Q1 2023. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Mendota Financial Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Mendota Financial Group sold 20 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $1.22K.
  • Mendota Financial Group first reported a position in Intra-Cellular Therapies Inc. in Q1 2023 and held it in 1 quarter.
  • Mendota Financial Group's Intra-Cellular Therapies Inc. position peaked at $1.22K in Q1 2023.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Mendota Financial Group's 13F filing for Q2 2023, filed 25 Jul 2023.